6th Annual CAR-TCR Summit Europe

Cell and gene therapy (CGT), including chimeric antigen receptor (CAR) T-cell therapy represents a new frontier in the fight against rare genetic disorders and cancers.

Complex study designs, challenging patient populations and distinct operational delivery requirements are the norm in CGT clinical trials. New treatment approaches are often unfamiliar to investigators, site staff and patients.

The Syneos Health Cell and Gene Therapy Development Engine, built upon nearly two decades of experience in the field, is the hub for our knowledge and experience in CGT preclinical/clinical development and commercialization, including CAR-T trials. It brings together the cross-functional capabilities needed to navigate the challenges unique to cell therapy trials, accelerate their development and deliver on their promise.

Meet with us at the 6^th Annual CAR-TRC Summit to discuss your CAR-T development or commercialization challenge.

Book a Meeting

FEATURED PRESENTATION:

Understanding the value in patient perceived experience and tolerance in CAR-T treatment

Wednesday, February 22: 5:30 p.m.

Anthony-Messina